Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $37,118 | 3 | 99.9% |
| Food and Beverage | $21.70 | 1 | 0.1% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| SANOFI US SERVICES INC. | $37,118 | 3 | $0 (2023) |
| TOLMAR Pharmaceuticals, Inc. | $21.70 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $37,118 | 3 | SANOFI US SERVICES INC. ($37,118) |
| 2022 | $21.70 | 1 | TOLMAR Pharmaceuticals, Inc. ($21.70) |
All Payment Transactions
4 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/14/2023 | SANOFI US SERVICES INC. | TZIELD (Biological) | — | Cash or cash equivalent | $32,838.29 | Research |
| Study: A Multicenter, Multinational Extension of Study PRV-031-001 to Evaluate the Long-Term Safety of Teplizumab (PRV-031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Children and Adolescents With Recent-Onset Type 1 Diabetes Mellitus • Category: Endocrine & Metabolic Diseases | ||||||
| 12/04/2023 | SANOFI US SERVICES INC. | TZIELD (Biological) | — | Cash or cash equivalent | $4,190.00 | Research |
| Study: A Multicenter, Multinational Extension of Study PRV-031-001 to Evaluate the Long-Term Safety of Teplizumab (PRV-031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Children and Adolescents With Recent-Onset Type 1 Diabetes Mellitus • Category: Endocrine & Metabolic Diseases | ||||||
| 12/04/2023 | SANOFI US SERVICES INC. | TZIELD (Biological) | — | Cash or cash equivalent | $90.00 | Research |
| Study: A Multicenter, Multinational Extension of Study PRV-031-001 to Evaluate the Long-Term Safety of Teplizumab (PRV-031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Children and Adolescents With Recent-Onset Type 1 Diabetes Mellitus • Category: Endocrine & Metabolic Diseases | ||||||
| 04/06/2022 | TOLMAR Pharmaceuticals, Inc. | FENSOLVI (Drug) | Food and Beverage | In-kind items and services | $21.70 | General |
| Category: Central Precocious Puberty (CPP) | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Multicenter, Multinational Extension of Study PRV-031-001 to Evaluate the Long-Term Safety of Teplizumab (PRV-031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Children and Adolescents With Recent-Onset Type 1 Diabetes Mellitus | SANOFI US SERVICES INC. | $37,118 | 3 |
About Dr. Wayne Moore, MD
Dr. Wayne Moore, MD is a Pediatric Endocrinology healthcare provider based in Kansas City, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1821045816.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Wayne Moore, MD has received a total of $37,140 in payments from pharmaceutical and medical device companies, with $37,118 received in 2023. These payments were reported across 4 transactions from 2 companies. The most common payment nature is "" ($37,118).
Practice Information
- Specialty Pediatric Endocrinology
- Location Kansas City, MO
- Active Since 05/27/2006
- Last Updated 06/17/2011
- Taxonomy Code 2080P0205X
- Entity Type Individual
- NPI Number 1821045816
Products in Payments
- TZIELD (Biological) $37,118
- FENSOLVI (Drug) $21.70
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatric Endocrinology Doctors in Kansas City
Dr. Joseph Cernich, M.d, M.D
Pediatric Endocrinology — Payments: $44,471
Dr. Matthew Feldt, D.o, D.O
Pediatric Endocrinology — Payments: $13,116
Dr. Mark Clements, Md, Phd, MD, PHD
Pediatric Endocrinology — Payments: $6,302
Dr. Julia Broussard, M.d, M.D
Pediatric Endocrinology — Payments: $3,393
Erica Zarse, Md, MD
Pediatric Endocrinology — Payments: $2,566
Figen Ugrasbul, M.d, M.D
Pediatric Endocrinology — Payments: $1,552